Peregrine has finished enrolling patients in their US Phase I clinical trial of bavituximab. The purpose of the trial is to find the maximum tolerated and/or effective dose of the drug while staying safe and tolerable in patients with advanced forms of cancer. Patients enrolled in the trial include people with breast, colorectal, pancreatic, liver, prostate, head and neck cancers and melanoma and mesothelioma.
This type of study can have helpful effects on the study and treatment of cancers such as mesothelioma. Officials at Peregrine believe that the results of this study coupled with the Phase II trial will set the stage for continuing late stage cancer studies. This could be very helpful in cases of mesothelioma.
If you or someone you know has been diagnosed with mesothelioma, contact the mesothelioma attorneys of Williams Kherkher at 800-781-3955.